Neurocrine Biosciences, Inc. (FRA:NB3)

Neurocrine Biosciences Statistics

Total Valuation

FRA:NB3 has a market cap or net worth of EUR 12.94 billion. The enterprise value is 12.39 billion.

Market Cap	12.94B
Enterprise Value	12.39B

Important Dates

The next estimated earnings date is Monday, February 9, 2026.

Earnings Date	Feb 9, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	99.71M
Shares Outstanding	n/a
Shares Change (YoY)	-1.30%
Shares Change (QoQ)	+1.49%
Owned by Insiders (%)	1.09%
Owned by Institutions (%)	99.92%
Float	98.54M

Valuation Ratios

The trailing PE ratio is 35.47 and the forward PE ratio is 15.76.

PE Ratio	35.47
Forward PE	15.76
PS Ratio	5.66
PB Ratio	5.05
P/TBV Ratio	5.12
P/FCF Ratio	25.60
P/OCF Ratio	23.84
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 22.82, with an EV/FCF ratio of 24.52.

EV / Earnings	33.98
EV / Sales	5.37
EV / EBITDA	22.82
EV / EBIT	26.67
EV / FCF	24.52

Financial Position

The company has a current ratio of 3.38, with a Debt / Equity ratio of 0.16.

Current Ratio	3.38
Quick Ratio	2.89
Debt / Equity	0.16
Debt / EBITDA	0.76
Debt / FCF	0.81
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 14.96% and return on invested capital (ROIC) is 10.41%.

Return on Equity (ROE)	14.96%
Return on Assets (ROA)	8.66%
Return on Invested Capital (ROIC)	10.41%
Return on Capital Employed (ROCE)	14.89%
Revenue Per Employee	1.27M
Profits Per Employee	202,658
Employee Count	1,800
Asset Turnover	0.69
Inventory Turnover	17.15

Taxes

In the past 12 months, FRA:NB3 has paid 170.97 million in taxes.

Income Tax	170.97M
Effective Tax Rate	31.91%

Stock Price Statistics

The stock price has increased by +7.26% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+7.26%
50-Day Moving Average	122.35
200-Day Moving Average	110.91
Relative Strength Index (RSI)	58.75
Average Volume (20 Days)	16

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.49

Income Statement

In the last 12 months, FRA:NB3 had revenue of EUR 2.29 billion and earned 364.78 million in profits. Earnings per share was 3.57.

Revenue	2.29B
Gross Profit	1.45B
Operating Income	460.50M
Pretax Income	535.76M
Net Income	364.78M
EBITDA	485.81M
EBIT	460.50M
Earnings Per Share (EPS)	3.57

Balance Sheet

The company has 950.14 million in cash and 408.85 million in debt, giving a net cash position of 541.30 million.

Cash & Cash Equivalents	950.14M
Total Debt	408.85M
Net Cash	541.30M
Net Cash Per Share	n/a
Equity (Book Value)	2.56B
Book Value Per Share	25.68
Working Capital	1.30B

Cash Flow

In the last 12 months, operating cash flow was 542.74 million and capital expenditures -37.25 million, giving a free cash flow of 505.50 million.

Operating Cash Flow	542.74M
Capital Expenditures	-37.25M
Free Cash Flow	505.50M
FCF Per Share	n/a

Margins

Gross margin is 63.21%, with operating and profit margins of 20.14% and 15.95%.

Gross Margin	63.21%
Operating Margin	20.14%
Pretax Margin	23.43%
Profit Margin	15.95%
EBITDA Margin	21.25%
EBIT Margin	20.14%
FCF Margin	22.11%

Dividends & Yields

FRA:NB3 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.30%
Shareholder Yield	1.30%
Earnings Yield	2.82%
FCF Yield	3.91%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:NB3 has an Altman Z-Score of 7.52 and a Piotroski F-Score of 4.

Altman Z-Score	7.52
Piotroski F-Score	4